bioSeedin

?? ?????????????? ???????????????? ???????????????? (??????????????) China's Next-Generation Oncology Innovators: A Deep Dive into BsAbs, ADCs, and Cell Therapies ?? Date: April 2nd, ?7-9 am BJT | April 1st, 7-9 PM EST ?? Format: Online As China's biopharma industry gains momentum globally, its advancements in bispecific antibodies (BsAbs), antibody-drug conjugates (ADCs), and cell therapies are attracting international attention. Join us to explore cutting-edge pipelines, strategic visions, and partnership opportunities with five leading Chinese biotech companies. Agenda Highlights: ?? Company Presentations: Discover the latest in BsAbs, ADCs, and cell therapies. ?? Global Partnerships: Insights into cross-border licensing and co-development deals. ?? Oncology Trends: Learn about the evolving landscape of global oncology deals. Agenda (EST): 7:00-7:10: Open Remarks 7:10-7:30: HanX Bio 7:30-7:50: CorreGene 7:50-8:10: KangaBio 8:10-8:30: ICT Bio 8:30-8:50: TBD 8:50-9:00: Summary Keynote Speakers: ?? Judge: Adrian He Adrian He, Business Development Project Leader, ROCHE Roche ??? Host: Kenneth C. Chen, Ph.D., MBA, Kenneth Chih-Wei Chen BD Manager (US & EU), bioSeedin bioSeedin Featured Companies: HanX Biopharmaceuticals: Next-gen immunotherapy (PD-1 & CTLA4). Kanga Biotechnology: Immunoagonist predrug molecules. Innovative Cellular Therapeutics Innovative Cellular Therapeutics (ICT): CoupledCAR? platform for solid tumors. CorreGene Biotechnology CorreGene Biotechnology : Novel T-cell Engagers based on TCR. ?? Register now to secure your spot and connect with China's leading oncology innovators! ??https://lnkd.in/gAfsp26k #OncologyInnovation #Biopharma #ChinaBiotech #ADCs #BsAbs #CellTherapy #InnoXpo #bioSeedin #PharmaDeals #BiotechNews

???????????????????????? ?????????????????? ???????????????? ?????????? ???? ?????????????? ?????? ??????-??????-???? ???? ?????? EnteroBiotix EnteroBiotix has reported promising topline data from its Phase 2a TrIuMPH study evaluating EBX-102-02, a full-spectrum microbiome-based drug, in patients with moderate to severe IBS with constipation (IBS-C). The treatment showed clinically meaningful improvements across key efficacy measures, including IBS symptom severity, stool consistency, and abdominal pain, with sustained benefits through follow-up. EBX-102-02 was also well-tolerated, with no serious adverse events. Microbiome analysis confirmed a significant shift in gut composition, supporting its potential as a first-in-class therapy for IBS. Final data, including results from IBS with diarrhea (IBS-D) patients, is expected in Q3 2025, with plans for a Phase 2b trial to further assess efficacy. #MicrobiomeTherapy #IBS #GutHealth #ClinicalTrials #Biotech #PharmaInnovation #EnteroBiotix

?????????????? ???????????????????????? ?????????????? ???????? ???? ?????? ?????? ????????????????? (????????????????????) ???? ???????? Travere Therapeutics Travere Therapeutics has submitted a supplemental New Drug Application (sNDA) to the FDA for FILSPARI? (sparsentan) as a potential treatment for focal segmental glomerulosclerosis (FSGS). If approved, FILSPARI could become the first FDA-approved therapy for this rare kidney disease, a leading cause of kidney failure. The submission is based on Phase 3 DUPLEX and Phase 2 DUET studies, which demonstrated that FILSPARI provided significant and sustained reductions in proteinuria, compared to irbesartan, in both pediatric and adult FSGS patients. The FDA review decision is expected in Q2 2025. Additionally, the FDA has determined that Risk Evaluation and Mitigation Strategy (REMS) monitoring for embryo-fetal toxicity is no longer necessary. Travere plans to amend its REMS submission accordingly while awaiting a decision on liver monitoring modifications, with a PDUFA target date of August 28, 2025. #Biopharma #RareDisease #KidneyDisease #FSGS #Nephrology #DrugDevelopment #FDAApproval #ClinicalTrials #Pharmaceuticals #HealthcareInnovation #TravereTherapeutics #PrecisionMedicine #MedicalResearch

?? We’re Hiring – Business Development Director/Manager ?? bioSeedin bioSeedin, a global leader in drug asset management & licensing, is looking for a Business Development Director/Manager to drive partnerships across the US, Europe, and Asia. ?? What You’ll Do: ? Identify & evaluate licensing opportunities ? Lead deal negotiations & project management ? Build relationships with biotech, pharma & VC partners ? Represent bioSeedin at global conferences ?? What We’re Looking For: ?? Master’s, PhD, or MD in life sciences ?? 5+ years in biotech/pharma/VC (3+ in BD) ?? Proven deal-making & industry connections ?? Salary: $110,000 - $140,000 DOE + Bonus/Commission Join us in shaping the future of biotech! Apply now! #Hiring #BusinessDevelopment #Biotech #Pharma #BD

?? ?????????????? ????.??????: ??????????? ???????????? ???????????? – ????????-??????????, ????????????????, ?????? ????????-?????????????????? ?????? ????????-?????? ?????????????????? Join us on March 26, 11:00 AM-12:00 PM (EDT) for an exclusive webinar with WuXi Biologics as they introduce EffiX?, a cutting-edge technology platform designed to enhance yield, scalability, and efficiency in microbial biologics production. ?? Agenda Highlights: ? Industry trends driving biologics innovation ? EffiX? platform deep dive ? Successful case studies ?? Speaker: Dr. Zhaopeng Li Dr. Zhaopeng Li, Senior Director, WuXi Biologics WuXi Biologics ?? Time: ?? EDT: March 26, 11:00 AM-12:00 PM ?? BST: March 26, 4:00-5:00 PM ?? Register now and explore how EffiX? accelerates biotherapeutic development! https://lnkd.in/gyEsBMcv?

?????????? ???????????????????????????? ???? ?????????????? ?????? ???????? ?????????????????? ?????????????? ???????????? ?????????????? Taiho Pharmaceutical Taiho Pharmaceutical Co., Ltd., has announced a definitive agreement to acquire Araris Biotech Araris Biotech AG, a Swiss biotech company specializing in next-generation antibody-drug conjugates (ADCs). The acquisition builds on a research collaboration between the two companies initiated in November 2023 and is expected to close in the first half of 2025. Key Deal Terms Total Deal Value: Up to $1.14 billion, including $400 million upfront payment Up to $740 million in milestone-based payments Araris’ Technology: Proprietary AraLinQ? platform offers: Highly stable and uniform ADCs Enhanced linker solubility, improving drug potency and reducing toxicity Pipeline of three ADC candidates in preclinical development, with clinical trials expected between 2025-2026 Strategic Impact By integrating Araris’ ADC technology with its Cysteinomix? small molecule drug discovery platform, Taiho Pharmaceutical aims to strengthen its oncology pipeline and accelerate the development of more precise and effective cancer treatments. Following the acquisition, Araris will continue its R&D operations in Zurich, Switzerland as a wholly owned subsidiary of Taiho. #ADCTherapy #Oncology #Biotech #Taiho #Araris #PharmaAcquisition

?????????????????????? ???? ?????????????? ?????????????????? ???? ?????????????? ???? ???????? ???????? ?????????????? ???????????????????????? AstraZeneca AstraZeneca has announced a definitive agreement to acquire EsoBiotec EsoBiotec, a biotechnology company pioneering in vivo cell therapies with a proprietary Engineered NanoBody Lentiviral (ENaBL) platform. Unlike traditional cell therapies, which require cell extraction and modification outside the body, EsoBiotec’s lentiviral vector technology enables direct genetic programming of immune cells within the patient, offering a faster, more accessible, and cost-effective alternative. Key Highlights of the Acquisition: ENaBL Platform: Uses targeted lentiviruses to program T cells and other immune cells to attack tumors or modulate immune responses. Simplified Cell Therapy: Eliminates the need for immune cell depletion and external cell engineering, reducing complexity and manufacturing time. Financial Terms: AstraZeneca will acquire EsoBiotec for up to $1 billion, including an initial $425 million payment and up to $575 million in milestone-based payments. Strategic Expansion: EsoBiotec will become a wholly owned subsidiary of AstraZeneca, operating from Belgium. Why This Matters AstraZeneca’s investment in cell therapy continues to expand, complementing its pipeline in CAR-T, TCR-T, and CAR-Treg therapies. This acquisition accelerates AstraZeneca’s goal of scaling next-generation cell therapies for oncology and immune-mediated diseases, making them more accessible and efficient for patients worldwide. #CellTherapy #Oncology #Biotech #AstraZeneca #EsoBiotec #Innovation

?? ?????????????? ???????????????? ????????????????: ?????????????????? ??????????’?? ????????-?????? ???????????????? ?????????????????????? China’s biotech industry is making remarkable strides in bispecific antibodies (BsAbs), ADCs, and cell therapies, fueling global oncology innovation. With increasing cross-border partnerships and licensing deals, Chinese biopharma assets are gaining international attention. Join us for an exclusive virtual roadshow featuring five leading biotech companies presenting their cutting-edge pipelines, clinical progress, and global collaboration opportunities in BsAbs, ADCs, and cell therapy. ?? Date & Time: ?? Apr 1 | 7-9 PM EST ?? Apr 2 | 7-9 AM BJT ?? Speakers from: ?? HanX Bio – Next-gen immunotherapy (PD-1 & CTLA-4) ?? CorreGene CorreGene Biotechnology – TCR-based T-cell engagers ?? KangaBio – Immunoagonist predrug molecules ?? ICT Bio Innovative Cellular Therapeutics (ICT) – CoupledCAR? for solid tumors ?? Register now to be part of this exclusive event and engage with China’s rising biotech leaders! ??https://lnkd.in/gAfsp26k

?????????????? ???????? ???????????????? ?????? ?????????? ?? ???????????????? ???????? ???? ?????? ???????? ?????? ???????????????????? Scholar Rock (NASDAQ: SRRK) Scholar Rock, a late-stage biopharmaceutical company focused on innovative treatments for neuromuscular diseases, presented new efficacy and safety data from the Phase 3 SAPPHIRE trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Dallas, Texas. The trial evaluated apitegromab, an investigational muscle-targeted therapy designed to improve motor function in spinal muscular atrophy (SMA) patients receiving SMN-targeted treatments. Key Findings from the SAPPHIRE Trial ?? Primary Endpoint Achieved: Apitegromab significantly improved motor function compared to placebo, as measured by the Hammersmith Functional Motor Scale Expanded (HFMSE) (p=0.0192). Clinically meaningful benefits were observed across key patient subgroups, regardless of age, SMN-targeted therapy type, or treatment initiation timing. ?? Secondary Endpoint Insights: 30.4% of patients receiving apitegromab showed a ≥3-point improvement in HFMSE vs. 12.5% on placebo (p=0.0156). Patients receiving apitegromab showed consistent gains across Revised Upper Limb Module (RULM) and WHO motor development milestones. ?? Safety & Tolerability: Apitegromab was well tolerated, with no treatment-related serious adverse events (SAEs). Pharmacokinetic data confirmed strong target engagement across both dose groups (10 mg/kg and 20 mg/kg). A Transformative Therapy for SMA Patients “The SAPPHIRE trial confirms that targeting muscle can offer additional functional improvements for SMA patients already on SMN-targeted therapies,” said Dr. Thomas O. Crawford, Professor of Neurology and Pediatrics at Johns Hopkins University. Scholar Rock’s CEO, Dr. Jay Backstrom Jay Backstrom, emphasized the urgency of bringing apitegromab to market globally: ?? “SMA patients continue to experience progressive muscle weakness despite current treatments. The SMA community is demanding more, and we are committed to delivering apitegromab as a breakthrough therapy.” Scholar Rock is preparing for regulatory submissions and plans to commercialize apitegromab in the U.S., Europe, and additional markets. #ScholarRock #SMA #NeuromuscularDisease #MuscleTargetedTherapy #MDA2025 #Apitegromab #BiotechNews

?????? ?????? ?????????????????? ?????? ???????????????????? ?????? ???????????? ???? ?????????????????? ???? ???????????????????? ???????????????? ???????????? Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) Zai Lab announced that China’s National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for TIVDAK (tisotumab vedotin-tftv) for the treatment of recurrent or metastatic cervical cancer in patients who have progressed on or after systemic therapy. “In China, cervical cancer remains a major health concern, with approximately 150,000 new cases diagnosed annually,” said Dr. Rafael Amado, M.D. Rafael Amado, President and Head of Global Research & Development at Zai Lab. “For patients facing recurrence or metastasis, treatment options are limited. TIVDAK, the first and only antibody-drug conjugate (ADC) for cervical cancer, has demonstrated a significant survival benefit in the pivotal global innovaTV 301 trial. If approved, it will complement our existing ZEJULA commercial infrastructure and expand our women’s cancer treatment portfolio.” Clinical Evidence Supporting the BLA: The submission is based on data from the global Phase 3 innovaTV 301 trial (NCT04697628), including results from the China subpopulation: ? 45% reduction in risk of death with TIVDAK vs. chemotherapy (HR: 0.55 [95% CI: 0.27-1.15]) ? Median overall survival (OS) was not reached for the TIVDAK arm, compared to 10.7 months in the chemotherapy arm ? Secondary endpoints, progression-free survival (PFS) and objective response rate (ORR), also favored TIVDAK ? Manageable safety profile, consistent with global data With this BLA acceptance, TIVDAK moves closer to becoming a potentially life-extending option for patients with advanced cervical cancer in China. #ZaiLab #TIVDAK #CervicalCancer #Oncology #ADC #Biologics #CancerTreatment